E(M)COP化疗方案治疗非何杰金淋巴瘤疗效分析

THERAPEUTIC EFFECTIVENESS OF E(M)COP CHEMOTHERAPY REGIMEN ON MALIGNANT NON-HODGKIN LYMPHOMA

目的 :探讨足叶乙甙或米托蒽醌联合化疗方案治疗非何杰金淋巴瘤的治疗效果。方法 :应用ECOP方案(足叶乙甙、环磷酰胺、长春新碱、强的松 )或MCOP方案 (米托蒽醌、环磷酰胺、长春新碱、强的松 )治疗 2 3例非何杰金淋巴瘤 ,其中ⅡA 2例、ⅢA 3例、ⅢB 3例、ⅣA 4例、ⅣB 11例 ,18例为初治病人 ,5例为复发病例。结果 :全组完全缓解率 (CR) 13例占 5 6 .5 %;部分缓解 (PR) 4例占 17.4%,总有效率 73.9%。其中初治 18例 ,总有效率 77.8%;复发 5例 ,总有效率 6 0 %。ECOP方案治疗 16例 ,CR率为 5 6 .5 %(9/ 16 ) ,PR为 18.8%(3/ 16 ) ,总有效率 73.3%,MCOP方案治疗 7例 ,CR率为 5 7.1%(4 / 7) ,部分缓解率 14.3%(1/ 17) ,总有效率71.4%。上述方案毒副作用有胃肠道反应 ,骨髓抑制 ,所有病例血象经间歇期应用或无G -CSF治疗均能恢复。结论 :ECOP或MCOP方案是治疗非何杰金淋巴瘤有效而较安全的方案。

Objective:To evaluate the effectiveness of Etoposide or Mitoxantrone combined chemotherapy in the treatment for malignant non-Hodgkin lymphoma(NHL).Methods:Combined chemotherapy of ECOP (Etoposide,Cyclophosphamide,Vincrisul and Prednisone)or MCOP Mitoxantrone,Cyclophosphamide,Vincrisul and Prednisone was used to treat 23 patients with malignant NHL.Among 23 cases,2 cases were Ann Arbor stage ⅡA,3 cases were ⅢA,3 cases were ⅢB,4 cases were ⅣA,and 11 cases were ⅣB.Eighteen cases were previously untreated NHL,and 5 cases were refractory and relapsed NHL.Results:Thirteen cases (56.5%) achieved complete remission (CR),and 4 cases (17.4%) achieved part remission (PR).The total remission rate was 73.9%(17/23).In 18 untreated cases,the total remission rate was 77.8%.In 5 refractory and relapsed cases,it was 60%.In 16 cases with treatment of ECOP regimen,CR rate,PR rate and total remission rate were 56.5%,18.8% and 73.3% respectively.In 7 cases with treatment of MCOP regimen,CR rate,PR rate and total remission rate were 57.1%,14.3% and 71.4% respectively.The main toxicity was gastrointestinal reaction and myelosuppression which could recover after the inverval periods of chemotherapy and with/without the treatment of G-CSF.Conclusions:The two kinds of chemotherapy are efficacious and safe remedies for NHL.